Acorda Therapeutics, Inc.
ACOR · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $3 | $3 | $4 | $6 |
| - Cash | $30 | $38 | $46 | $71 |
| + Debt | $191 | $173 | $191 | $260 |
| Enterprise Value | $164 | $138 | $150 | $194 |
| Revenue | $118 | $119 | $129 | $153 |
| % Growth | -0.8% | -8.1% | -15.6% | – |
| Gross Profit | $72 | $88 | $88 | $119 |
| % Margin | 60.9% | 74.4% | 68.4% | 78.1% |
| EBITDA | -$202 | -$10 | -$45 | -$65 |
| % Margin | -171.6% | -8.5% | -34.7% | -42.5% |
| Net Income | -$253 | -$66 | -$104 | -$100 |
| % Margin | -215% | -55.6% | -80.5% | -65.1% |
| EPS Diluted | -203.59 | -66.9 | -195.75 | -246.4 |
| % Growth | -204.3% | 65.8% | 20.6% | – |
| Operating Cash Flow | -$14 | -$21 | -$41 | -$61 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$4 |
| Free Cash Flow | -$14 | -$21 | -$42 | -$65 |